A review on peptic ulcer
DOI:
https://doi.org/10.37022/jpmhs.v5i1.73Keywords:
Peptic ulcers, proton pump inhibitors, gastrointestinal tract, Non-steroidal anti-inflammatory drugs and Helicobacter pyloriAbstract
Peptic ulcer is a chronic disease affecting up to 10% of the world’s population. The formation of peptic ulcers depends on the presence of gastric juice pH and the decrease in mucosal defences. Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori (H. pylori) infection are the two major factors disrupting the mucosal resistance to injury. Peptic ulcer disease (PUD) is characterized by discontinuation in the inner lining of the gastrointestinal (GI) tract because of gastric acid secretion or pepsin. It extends into the muscularis propria layer of the gastric epithelium. It usually occurs in the stomach and proximal duodenum. It may involve the lower esophagus, distal duodenum, or jejunum. Epigastric pain usually occurs within 15-30 minutes following a meal in patients with a gastric ulcer; on the other hand, the pain with a duodenal ulcer tends to occur 2-3 hours after a meal. The treatments of peptic ulcers, such as proton pump inhibitors (PPIs) and histamine-2 (H2) receptor antagonists, have demonstrated adverse effects, relapses, and various drug interactions. On the other hand, medicinal plants and their chemical compounds are useful in the prevention and treatment of numerous diseases. Hence, this review presents common medicinal plants that may be used for the treatment or prevention of peptic ulcers.
Downloads
References
Narayanan M, Reddy KM, Marsicano E. Peptic Ulcer Disease and Helicobacter pylori infection. Mo Med. 2018 May-Jun;115(3):219-224.
Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, Sostres C, García-Rodríguez LA. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015 May;13(5):906-12.e2.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002 Jan 05;359(9300):14-22.
Siddique, O.; Ovalle, A.; Siddique, A.S.; Moss, S.F. Helicobacter pylori infection: An update for the internist in the age of increasing global antibiotic resistance. Am. J. Med. 2018, 131, 473–479.
Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017, 153, 420–429.
Bhat S . SRB's Manual of Surgery. 2013: 364.
Zaki, M.; Coudron, P.E.; McCuen, R.W.; Harrington, L.; Chu, S.; Schubert, M.L. H. Pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304, G715–G722.
El-Omar, E.M.; Oien, K.; El-Nujumi, A.; Gillen, D.; Wirz, A.; Dahill, S.; Williams, C.; Ardill, J.E.; McColl, K.E. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997, 113, 15–24. [CrossRef]
Moss, S.F.; Legon, S.; Bishop, A.E.; Polak, J.M.; Calam, J. Effect of helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992, 340, 930–932.
Bhala, N.; Emberson, J.; Merhi, A.; Abramson, S.; Arber, N.; Baron, J.A.; Bombardier, C.; Cannon, C.; Farkouh, M.E.; FitzGerald, G.A.; et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 2013, 382, 769–779.
Bjarnason, I.; Scarpignato, C.; Takeuchi, K.; Rainsford, K.D. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment. Pharmacol. Ther. 2007, 26, 95–106.
Aihara T, Nakamura E, Amagase K, Tomita K, Fujishita T, Furutani K et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacol Ther 2003;98:109-127.
Tasman-Jones C. Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. Scand J Gastroenterol. 1986; 21: 1-5.
Lindstrom E, Chen D, Norlen P, Andersson K, and Hakanson R. Control of gastric acid secretion: the gastrin-ECL cell-parietal cell axis. Comp Biochem Physiol A Mol Integr Physiol 2001;128: 505–514.
Terence C, Enrique R. CCK2 receptor mediates rapid protein kinase D activation through a protein kinase C-dependent pathway. FEBS Lett 2001;489:101-106.
Waldum HL, Kleveland PM, Sandvik AK, Brenna E, Syversen U, Bakke I, and Tommeras K. The cellular localization of the cholecystokinin 2 receptor in the stomach. Pharmacol Toxi col 2002;91:359–362.
Hunyady BL, Lyomi ARZ, Hoffman BJ, Mezey EV. Gastrin-Producing Endocrine Cells: A Novel Source of Histamine in the Rat Stomach. Endocrinology 1998;139:4404-4415.
Sandvik AK, Kleveland PM, Waldum HL. Muscarinic M2 stimulation releases histamine in the t otally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1988;23: 1049-56.
Published
How to Cite
Issue
Section
Citations
Copyright (c) 2022 K. Jaswanth, C.Kiran Kumar, P. Venkatesh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.